Scientific ReportsCancer BiologyPeer-reviewed journal article
Modulating the unfolded protein response: Impacts of radiation on the response of prostate cancer cells to ONC201
F. Amoroso, K. Glass, F. Liberal, R. Steele, S. Maguire, R. Tarapore, J. Allen, S. Van Schaeybroeck, K. Butterworth, K. Prise, J. O'Sullivan, S. Jain, D. Waugh, I. Mills
Abstract
Prostate cancer (PCa) is the most common non-cutaneous cancer in men and a notable cause of cancer mortality when it metastasises. Localised disease is mostly treated with surgery or radiotherapy. As PCa develops and treatment resistance emerges, the unfolded protein response (UPR) arises as an important adaptive biology co-amplifying with key cancer drivers [1]. The UPR can be cytoprotective but when acutely activated can lead to cell death. In this study we sought to enhance the acute activation of the UPR using radiation and ONC201, previously reported to be an UPR activator [2]. We found that treating PCa cells with ONC201 quickly increases the expression of components in all arms of the UPR - ATF4, ATF6 and IRE1-XBP1 - culminating in the subsequent cell death. During this time window between UPR activation and cell death we tested the priming effect of short-term administration of ONC201 on radiation responses. Pre-treatment with ONC201 for 24 hours prior to irradiation led to enhanced cytotoxicity compared to radiation alone assessed by cell viability and clonogenic assays. With priming, RNA-Seq analysis showed a sustained suppression of transcripts encoding cell cycle regulators as well as components of the DNA damage response pathways. Phenotypically this was reflected in enhanced cell cycle arrest and induction of necrosis and apoptosis. Furthermore, we demonstrated that short-term administration of inhibitors of cell cycle regulators (Dinaciclib and BI2536), could replicate this priming effect. Thus, we propose future studies to assess the impact of the short-term administration of drugs targeting the UPR and cell cycle regulation to enhance radiotherapy response.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.
Dimitrios Doultsinos, Ingrid Tomljanović, … Ian Geoffrey Mills·bioRxiv·Mar 13, 2025
- Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells
Kenichi Kudo, Qianhua Feng, … Yun Rose Li·bioRxiv·Dec 5, 2025
- Radiopotentiation of Enzalutamide over Human Prostate Cancer Cells as Assessed by Real-Time Cell Monitoring
M. Barrado, I. Blanco-Luquin, … F. Arias·bioRxiv·May 17, 2018
- IRF7 impacts on prostate cancer cell survival in response to radiation
A. Pickard, F. Amoroso, … I. Mills·bioRxiv·Sep 23, 2022
- HNRNPA2B1 controls an unfolded protein response-related prognostic gene signature in prostate cancer
J. G. Foster, E. E. M. Gea, … P. Rajan·bioRxiv·Jun 21, 2022
- Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein